๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 4 Shanghai 4 Jinan 4 Chengdu 2 Fuzhou 2
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing4 Shanghai4 Jinan4 Chengdu2 Fuzhou2
All 15 locations
Target enrolment
to

Trials with a site in Beijing

4 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT07603479Malignancies, Solid Malignant Tumor, NHL (Non-Hodgkin Lymphoma), Solid Tumor Cancer
Jecho Biopharmaceuticals Co., Ltd.
Phase 1
14
Beijing
2026-06-25
Recruiting
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
NCT07441174Solid Tumor Cancer, PDAC
InxMed (Shanghai) Co., Ltd.
Phase 1/2
92
Beijing, Fuzhou, Guangzhou, Zhengzhou, Luoyang, Changsha, Nanjing, Shengyang
2026-02-28
Not yet open
A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT07046780Solid Tumor Cancer, Metastatic Solid Tumors, Locally Advanced
PENG YUAN
Observational
90
Beijing
2025-07-30
Recruiting
Study of GV20-0251 in Participants With Solid Tumor Malignancies
NCT07070518Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
GV20 Therapeutics
Phase 1/2
350
Beijing, Shanghai
2025-07-11
Rows per page Showing 1–4 of 4
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 4 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

3 of the 4 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 4 studies
PhaseStudiesRecruitingShare
Phase 1/22250%
Observational1025%
Phase 11125%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
GV20 Therapeutics11
InxMed (Shanghai) Co., Ltd.11
Jecho Biopharmaceuticals Co., Ltd.11
PENG YUAN10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.